Chemical Compound Review:
NSC-132087 N,2-dihydroxy-3-methyl- benzamide
Synonyms:
NSC132087, AR-1K0328, AKOS000185630, AC1L5SC3, AC1Q5EO0, ...
- Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. Kévorkian, J.P., Michel, C., Hofmann, U., Jacqz-Aigrain, E., Kroemer, H.K., Peraldi, M.N., Eichelbaum, M., Jaillon, P., Funck-Brentano, C. Clin. Pharmacol. Ther. (1996)
- Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Tyndale, R.F., Sunahara, R., Inaba, T., Kalow, W., Gonzalez, F.J., Niznik, H.B. Mol. Pharmacol. (1991)
- Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Sindrup, S.H., Brøsen, K., Gram, L.F. Clin. Pharmacol. Ther. (1992)
- The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. Christensen, P.M., Gøtzsche, P.C., Brøsen, K. Pharmacogenetics (1998)
- Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Sindrup, S.H., Brøsen, K., Bjerring, P., Arendt-Nielsen, L., Larsen, U., Angelo, H.R., Gram, L.F. Clin. Pharmacol. Ther. (1990)
- Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Gaedigk, A., Blum, M., Gaedigk, R., Eichelbaum, M., Meyer, U.A. Am. J. Hum. Genet. (1991)
- Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo. Manns, M., Zanger, U., Gerken, G., Sullivan, K.F., Meyer zum Büschenfelde, K.H., Meyer, U.A., Eichelbaum, M. Hepatology (1990)
- Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. Kagimoto, M., Heim, M., Kagimoto, K., Zeugin, T., Meyer, U.A. J. Biol. Chem. (1990)
- Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. Gut, J., Catin, T., Dayer, P., Kronbach, T., Zanger, U., Meyer, U.A. J. Biol. Chem. (1986)
- Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme. Distlerath, L.M., Guengerich, F.P. Proc. Natl. Acad. Sci. U.S.A. (1984)
- The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. Eichelbaum, M., Gross, A.S. Pharmacol. Ther. (1990)
- The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. Mikus, G., Gross, A.S., Beckmann, J., Hertrampf, R., Gundert-Remy, U., Eichelbaum, M. Clin. Pharmacol. Ther. (1989)
- Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Nielsen, K.K., Brøsen, K., Hansen, M.G., Gram, L.F. Clin. Pharmacol. Ther. (1994)
- Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. Ellis, S.W., Ching, M.S., Watson, P.F., Henderson, C.J., Simula, A.P., Lennard, M.S., Tucker, G.T., Woods, H.F. Biochem. Pharmacol. (1992)
- Sparteine increases insulin release by decreasing the K+ permeability of the B-cell membrane. Paolisso, G., Nenquin, M., Schmeer, W., Mathot, F., Meissner, H.P., Henquin, J.C. Biochem. Pharmacol. (1985)
- Aminopyridines and sparteine as inhibitors of membrane potassium conductance: effects on Myxicola giant axons and the lobster neuromuscular junction. Schauf, C.L., Colton, C.A., Colton, J.S., Davis, F.A. J. Pharmacol. Exp. Ther. (1976)
- Sparteine oxidation by the human liver: absence of inhibition by mephenytoin. Jurima, M., Inaba, T., Kalow, W. Clin. Pharmacol. Ther. (1984)
- The relationship between paroxetine and the sparteine oxidation polymorphism. Sindrup, S.H., Brøsen, K., Gram, L.F., Hallas, J., Skjelbo, E., Allen, A., Allen, G.D., Cooper, S.M., Mellows, G., Tasker, T.C. Clin. Pharmacol. Ther. (1992)
- Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Lennard, M.S., Iyun, A.O., Jackson, P.R., Tucker, G.T., Woods, H.F. Pharmacogenetics (1992)
- Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. Schellens, J.H., van der Wart, J.H., Brugman, M., Breimer, D.D. J. Pharmacol. Exp. Ther. (1989)
- Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Yokota, H., Tamura, S., Furuya, H., Kimura, S., Watanabe, M., Kanazawa, I., Kondo, I., Gonzalez, F.J. Pharmacogenetics (1993)
- 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. Granvil, C.P., Krausz, K.W., Gelboin, H.V., Idle, J.R., Gonzalez, F.J. J. Pharmacol. Exp. Ther. (2002)
- Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese. Yokoi, T., Kamataki, T. Pharm. Res. (1998)
- Mechanism of cytochrome P450 2D6-catalyzed sparteine metabolism in humans. Ebner, T., Meese, C.O., Eichelbaum, M. Mol. Pharmacol. (1995)
- Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Liou, Y.J., Wang, Y.C., Bai, Y.M., Lin, C.C., Yu, S.C., Liao, D.L., Lin, M.W., Chen, J.Y., Lai, I.C. Neuropsychobiology (2004)
- The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Skjelbo, E., Brøsen, K., Hallas, J., Gram, L.F. Clin. Pharmacol. Ther. (1991)